默沙东2025H1：K药152亿美元，HPV疫苗25亿美元，启动成本优化计划

医药魔方Info2025-07-29

7月29日，默沙东公布2025H1业绩，上半年总营收313.35亿美元，同比下降2%。默沙东制药业务收入276.88亿美元，同比下降3%。其中，中国区收入同比下滑70%至10.75亿美元，占据默沙东全球制药业务3.9%的份额。值得注意的是，默沙东还在半年报公布之际宣布启动一项新的多年期优化计划，旨在通过生产力行动预计每年节省30亿美元的成本来实现其产品组合的转型，这些成本将全部再投资以支持新产品的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555557220?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-29 19:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555557220","market":"us","top_or_hot":-1,"title":"默沙东2025H1：K药152亿美元，HPV疫苗25亿美元，启动成本优化计划","media":"医药魔方Info","content":"<div>\n<p>7月29日，默沙东公布2025H1业绩，上半年总营收313.35亿美元，同比下降2%。默沙东制药业务收入276.88亿美元，同比下降3%。其中，中国区收入同比下滑70%至10.75亿美元，占据默沙东全球制药业务3.9%的份额。值得注意的是，默沙东还在半年报公布之际宣布启动一项新的多年期优化计划，旨在通过生产力行动预计每年节省30亿美元的成本来实现其产品组合的转型，这些成本将全部再投资以支持新产品的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291946229725576a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东2025H1：K药152亿美元，HPV疫苗25亿美元，启动成本优化计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东2025H1：K药152亿美元，HPV疫苗25亿美元，启动成本优化计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 19:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291946229725576a&s=b><strong>医药魔方Info</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月29日，默沙东公布2025H1业绩，上半年总营收313.35亿美元，同比下降2%。默沙东制药业务收入276.88亿美元，同比下降3%。其中，中国区收入同比下滑70%至10.75亿美元，占据默沙东全球制药业务3.9%的份额。值得注意的是，默沙东还在半年报公布之际宣布启动一项新的多年期优化计划，旨在通过生产力行动预计每年节省30亿美元的成本来实现其产品组合的转型，这些成本将全部再投资以支持新产品的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291946229725576a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BBT3K403.USD","symbol_name":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291946229725576a&s=b","article_id":"2555557220","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291946229725576a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555557220","pubTimestamp":1753787784,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月29日，默沙东公布2025H1业绩，上半年总营收313.35亿美元，同比下降2%。默沙东制药业务收入276.88亿美元，同比下降3%。作为该计划的一部分，默沙东于7月批准了一项新的重组计划。默沙东另一王牌产品HPV疫苗Gardasil/Gardasil 9上半年销售额为24.53亿美元，同比下降48%。默沙东已落实应对之策，率先开拓中国HPV疫苗的男性市场。展望2025全年，默沙东预计全球销售额将在643亿美元至653亿美元之间。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4007":"制药","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","MRK":"默沙东","BK4534":"瑞士信贷持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC"},"translate_title":"Merck 2025H1: K drug US $15.2 billion, HPV vaccine US $2.5 billion, start cost optimization plan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"7月29日，默沙东公布2025H1业绩，上半年总营收313.35亿美元，同比下降2%。默沙东制药业务收入276.88亿美元，同比下降3%。其中，中国区收入同比下滑70%至10.75亿美元，占据默沙东全球制药业务3.9%的份额。值得注意的是，默沙东还在半年报公布之际宣布启动一项新的多年期优化计划，旨在通过生产力行动预计每年节省30亿美元的成本来实现其产品组合的转型，这些成本将全部再投资以支持新产品的发布及其跨多个治疗领域的产品线。作为该计划的一部分，默沙东于7月批准了一项新的重组计划。公司预计在此计划中将裁撤部分行政、销售和研发岗位。然而，默沙东将继续在业务的战略增长领域招聘员工担任新职位。此外，默沙东将缩减其全球地产足迹，并持续优化其制造网络，使其全球制造布局的地理分布与客户需求相匹配。默沙东预计重组计划下的行动每年将节省约17亿美元的成本，并将在2027年底前基本实现。此项重组计划是多年期优化计划的一部分，该优化计划预计到2027年底将实现30亿美元的年度成本节约。今年上半年，药王Keytruda（帕博利珠单抗）的销售额达151.61亿美元，不过增势已趋缓，同比增长7%。其他的肿瘤产品也均在增长之中。全球首创HIF-2α抑制剂Welireg上半年取得3.00亿美元的销售额，同比增长42%。Lynparza（奥拉帕利）和Lenvima（仑伐替尼）则分别为默沙东带来了6.82亿美元和5.23亿美元的收入分成。默沙东另一王牌产品HPV疫苗Gardasil/Gardasil 9上半年销售额为24.53亿美元，同比下降48%。在2024Q3财报中，Gardasil系列产品就初显颓势，主要原因在于中国地区的需求减少。而需求减少的背后，与激烈的竞争息息相关，首个中国国产九价已获批上市。默沙东已落实应对之策，率先开拓中国HPV疫苗的男性市场。今年4月，Gardasil 9在华获批新适应证，适用于16-26岁男性接种。这也是中国境内首个且唯一获批、可适用于适龄男性女性的九价HPV疫苗。HPV疫苗之外，默沙东也迅速更新迭代其他疫苗产品。2024年6月，21价肺炎球菌结合疫苗Capvaxive获批上市，今年上半年创收2.36亿美元。该产品与Pneumovax 23和Vaxneuvance（15价）形成更全面的肺炎球菌疫苗产品布局，后两者在今年上半年的销售额分别为0.79亿美元（-35%）和4.59亿美元（+13%）。心血管领域，肺动脉高压（PAH）新药Winrevair无疑是默沙东业绩中一颗冉冉升起的新星。该药物于2024年3月在美国获批上市，成为第一个被批准用于治疗PAH的激活素信号抑制剂疗法，仅需每3周皮下注射一次。今年上半年，Winrevair就交出了6.15亿美元的亮眼成绩单。也就是说，Winrevair在上市后的首个完整年度就能长成重磅炸弹。口服PCSK9抑制剂enlicitide decanoate和GLP-1R/GCGR双重激动剂Efinopegdutide也被默沙东寄予厚望。前者已在今年6月传来两项治疗高胆固醇血症III期研究（CORALreef HeFH和CORALreef AddOn）成功的好消息。抗感染领域，RSV单抗Clesrovimab已在美获批上市，成为首个且唯一一款无论体重如何均采用相同剂量适用于婴儿的RSV预防方案。展望2025全年，默沙东预计全球销售额将在643亿美元至653亿美元之间。Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555557220","isCrawlerRequest":true}